GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » MaxCyte Inc (NAS:MXCT) » Definitions » EBIT

MXCT (MaxCyte) EBIT : $-46.39 Mil (TTM As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is MaxCyte EBIT?

MaxCyte's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was $-14.05 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was $-46.39 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. MaxCyte's annualized ROC % for the quarter that ended in Sep. 2024 was -65.80%. MaxCyte's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -152.20%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. MaxCyte's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -14.70%.


MaxCyte EBIT Historical Data

The historical data trend for MaxCyte's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MaxCyte EBIT Chart

MaxCyte Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -12.21 -10.99 -18.04 -27.36 -48.30

MaxCyte Quarterly Data
Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.95 -8.10 -12.28 -11.97 -14.05

Competitive Comparison of MaxCyte's EBIT

For the Medical Devices subindustry, MaxCyte's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MaxCyte's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, MaxCyte's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where MaxCyte's EV-to-EBIT falls into.



MaxCyte EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-46.39 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MaxCyte  (NAS:MXCT) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

MaxCyte's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=-56.212 * ( 1 - 0% )/( (86.137 + 84.719)/ 2 )
=-56.212/85.428
=-65.80 %

where

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=248.612 - 10.061 - ( 153.832 - max(0, 17.621 - 172.909+153.832))
=84.719

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

MaxCyte's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-56.212/( ( (32.728 + max(6.92, 0)) + (31.855 + max(2.363, 0)) )/ 2 )
=-56.212/( ( 39.648 + 34.218 )/ 2 )
=-56.212/36.933
=-152.20 %

where Working Capital is:

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(4.581 + 11.159 + 2.577) - (8.029 + 3.368 + 0)
=6.92

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(4.56 + 10.393 + 4.124) - (10.061 + 6.653 + 0)
=2.363

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

MaxCyte's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2024 )
=-46.392/315.566
=-14.70 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MaxCyte EBIT Related Terms

Thank you for viewing the detailed overview of MaxCyte's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


MaxCyte Business Description

Traded in Other Exchanges
Address
9713 Key West Avenue, Suite 400, Rockville, MD, USA, 20850
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
Executives
Stanley C Erck director 20 FIRSTFIELD ROAD, #250, GAITHERSBURG MD 20878
John Joseph Johnston director C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Thomas M. Ross officer: EVP, Global Sales C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Maher Masoud officer: EVP and General Counsel C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Douglas Doerfler director, officer: President and CEO C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Richard Douglas director ONE KENDALL SQUARE, CAMBRIDGE MA 02139
Douglas J Swirsky officer: Chief Financial Officer C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD 20850
Patrick J Balthrop director C/O MAXCYTE, INC., 9713 KEY WEST AVENUE, SUITE 400, ROCKVILLE MD 20850
Casdin Partners Master Fund, L.p. 10 percent owner WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001
Cenk Sumen officer: Chief Scientific Officer C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Amanda Louise Murphy officer: Chief Financial Officer C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Ron Holtz officer: SVP and CAO C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Yasir B. Al-wakeel director MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Art Mandell director C/O MAXCYTE, INC., C/O 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
William W Brooke director 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203